Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, ...

Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...

Yesterday, the U.S. Court of Appeals for the Federal Circuit issued a precedential decision vacating the Patent Trial and ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

The board of Merck KGaA ( ETR:MRK ) has announced that it will pay a dividend of €2.20 per share on the 30th of ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Out of all of the special options we uncovered, 3 are puts, for a total amount of $141,686, and 10 are calls, for a total ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...

What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...

Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.

MilliporeSigma Chief Technology Officer Brings Extensive Science, Technology, and Innovation Leadership Experience Wiley (NYSE: WLY), one of the world's largest publishers and a trusted leader in ...